Clinical Trial Update: BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating bempeg with pembrolizumab versus pembrolizumab alone in metastatic or recurrent head and neck cancer was terminated; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• bempeg with pembrolizumab

Snippet

Sponsor: Nektar Therapeutics | Conditions: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-12-15